Identification of novel FFA1 and GPR120 ligands and their use in elucidating the pharmacology, function, and clinical utility of these receptors in the treatment of obesity and diabetes.

新型 FFA1 和 GPR120 配体的鉴定及其在阐明这些受体在治疗肥胖和糖尿病中的药理学、功能和临床用途中的应用。

• 批准号: 225262
• 负责人: Hudson Brian D
• 金额: $ 10.93万
• 依托单位: University of Glasgow (Scotland)
• 依托单位国家: 加拿大
• 项目类别: Fellowship Programs
• 财政年份: 2011
• 资助国家: 加拿大
• 起止时间: 2011-02-01 至 2014-02-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=225262&lang=en
• 关键词: Diabetes; Ffa1; Free Fatty Acid; G Protein Coupled Receptor; Gpr120; Obesity

G protein coupled receptors are a large family of proteins responsible for producing many different biological effects. Not only are these receptor proteins the most common target for currently available drugs, but they are also known to respond to a gre

G蛋白偶联受体是一个负责产生许多不同生物学效应的蛋白质大家族。 这些受体蛋白不仅是目前可用药物的最常见靶点，而且已知它们对GRE有反应。